Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706799 | 0.91 | SLC2A1 (0.44) | SLC2A1 | |
| SCHEMBL6147587 | 0.91 | SLC2A1 (0.48) | ALDH1A1SLC2A1MEN1KMT2APOLB | |
| SCHEMBL6145300 | 0.91 | KCNH2 (0.45) | ALDH1A1SLC2A1MEN1KMT2APOLB | |
| SCHEMBL6149475 | 0.89 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2APOLBLMNA | |
| SCHEMBL6145877 | 0.86 | SLC2A1 (0.42) | SLC2A1 | |
| SCHEMBL6143755 | 0.85 | MEN1 (0.52) | ALDH1A1MEN1KMT2APOLBP4HB | |
| SCHEMBL6143468 | 0.85 | MEN1 (0.46) | ALDH1A1MEN1KMT2APOLBP4HB | |
| SCHEMBL6143336 | 0.84 | SLC2A1 (0.40) | SLC2A1 | |
| SCHEMBL6143396 | 0.84 | SLC2A1 (0.40) | SLC2A1 | |
| SCHEMBL445305 | 0.83 | MAPT (0.40) | ALDH1A1SLC2A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481735-A1 | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2155716-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | Pfizer Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008139288-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| US-6903217-B2 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-06-07 | — | — | US | disclosed |
| US-20040147518-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. | 2004-07-29 | — | — | US | disclosed |
| US-6603005-B2 | Bactericides | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | NOVEXEL (FR) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147518-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | SYNJ1, NCAPD2, SYNJ2 | ALDH1A1 838/4885SLC2A1 4311/4885MEN1 250/4885 |
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | SYNJ1, NCAPD2, SYNJ2 | ALDH1A1 838/4885SLC2A1 4311/4885MEN1 250/4885 |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | ALDH1A1 3777/4885SLC2A1 4192/4885MEN1 540/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | ALDH1A1 3777/4885SLC2A1 4192/4885MEN1 540/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | ALDH1A1 3777/4885SLC2A1 4192/4885MEN1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.